| 5.33 0.15 (2.9%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.2 | 1-year : | 9.63 |
| Resists | First : | 7.02 | Second : | 8.25 |
| Pivot price | 6.74 |
|||
| Supports | First : | 5.03 | Second : | 4.19 |
| MAs | MA(5) : | 5.38 |
MA(20) : | 6.75 |
| MA(100) : | 7.82 |
MA(250) : | 12.94 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 8.7 |
D(3) : | 9.4  |
| RSI | RSI(14): 33.9 |
|||
| 52-week | High : | 29.97 | Low : | 5.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MCRB ] has closed above bottom band by 17.5%. Bollinger Bands are 95.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.69 - 5.74 | 5.74 - 5.77 |
| Low: | 5.06 - 5.1 | 5.1 - 5.13 |
| Close: | 5.28 - 5.34 | 5.34 - 5.39 |
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
Fri, 10 Jul 2026
Seres Therapeutics (MCRB) director Kurt Graves receives 6,500 stock options at $7.14 - Stock Titan
Fri, 10 Jul 2026
Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14 - Stock Titan
Fri, 10 Jul 2026
Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer - Stock Titan
Fri, 10 Jul 2026
Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere - Stock Titan
Fri, 10 Jul 2026
Seres Therapeutics (MCRB) director receives 6,500 stock options at $7.14 strike - Stock Titan
Fri, 10 Jul 2026
Seres Therapeutics (MCRB) awards 25,000-share stock option grant to officer Henn - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 8.47e+006 (%) |
| Held by Institutions | 11.7 (%) |
| Shares Short | 479 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.38e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 839.9 % |
| Return on Equity (ttm) | -38.9 % |
| Qtrly Rev. Growth | 1.15e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -1354.12 |
| EBITDA (p.s.) | -5.81111e+008 |
| Qtrly Earnings Growth | -5.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.17 |
| Dividend | 0 |
| Forward Dividend | 157330 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|